# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A p...
Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorderSocial anxiety di...
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of...
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on reven...
Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demon...
Jefferies analyst Andrew Tsai upgrades Vistagen Therapeutics (NASDAQ:VTGN) from Hold to Buy and raises the price target from...